Search results
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
Benzinga via AOL· 19 hours agoTogether with the domestic Sanofi (NASDAQ: SNY), Pfizer, AstraZeneca will together invest €1.87...
Novavax Soars on Sanofi Deal: A Smart Buy or Post-Hype Correction?
FX Empire via Yahoo Finance· 2 days agoThe past five days have been a rollercoaster for Novavax investors, as the share price of the...
Sanofi to Spend $1.08 Billion to Boost Drug Production in France
Morningstar· 4 days agoSanofi will spend more than 1 billion euros ($1.08 billion) on ramping up production capability in France. The French pharmaceutical company said Monday ...
French, US drug firms team up for Covid-flu shot
Medical Xpress· 7 days agoFrench pharmaceutical giant Sanofi and struggling US rival Novavax announced Friday an alliance to sell a COVID vaccine and develop another that combines...
Sanofi to make €1bn biomanufacturing investment in France
Pharmaceutical Technology via Yahoo Finance· 3 days agoBefore this development, Sanofi entered a $1bn licensing agreement with Fulcrum Therapeutics. The...
Novavax shares jump 40% on $1.2 billion licensing deal with Sanofi despite Q1 losses | Invezz
Invezz· 7 days agoNovavax (NASDAQ:NVAX) shares rocketed 40% in premarket trading Friday, driven not only by the...
Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
Zacks via Yahoo Finance· 4 days agoSanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with...
Does Soaring Novavax Stock Have Enough Fuel to Climb Higher? | The Motley Fool
The Motley Fool· 3 days agoThe market was responding to terrific news from Sanofi (NASDAQ: SNY), a global pharmaceutical giant...
Sartorius Collaborates With Sanofi to Commercialize End-to-End Platform for Downstream Process...
NewMediaWire via Yahoo Finance· 3 days agoSartorius selected as preferred partner for development and commercialization of integrated and...
Sanofi pays $80M to add Roche-rivaling Fulcrum drug to phase 3 rare disease pipeline
FierceBiotech· 4 days agoSanofi is betting $80 million upfront on a GSK castoff ahead of a phase 3 readout. Fulcrum Therapeutics took the other side of the deal, handing Sanofi ...